Skip to main content
SpringerLink
Log in

Neue Therapieaspekte bei Rezidiv und Fernmetastase des Kopf- und Hals-Karzinoms

Highlights vom ASCO-Kongress 2012

New aspects in the therapy of recurrence and metastasis of head and neck cancer

Highlights from the 2012 ASCO meeting

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Der überwiegende Anteil von Patienten mit einem Plattenepithelkarzinom der Kopf- und Halsregion („head and neck squamous cell carcinoma“, HNSCC) präsentiert sich bereits bei der Erstvorstellung in einem regional sehr fortgeschrittenen Stadium der Erkrankung. Einige dieser Patienten entwickeln trotz mitunter sehr aggressiver Behandlungsprotokolle in der Erstlinientherapie ein lokoregionäres Rezidiv oder Metastasen. Dieses Patientengut stellt eine besondere Herausforderung an das multidisziplinäre Behandlungsteam dar. Neben Operabilität und vorangegangener Therapie müssen daher auch Patientenalter, der Leistungsstatus und die individuellen Wünsche des Patienten in die Entscheidungsfindung mit einbezogen werden. Abgesehen von chirurgischen Optionen wie der Salvage-Chirurgie stellen die Chemo- und die Target-Therapie sowie die Reradiatio mögliche Behandlungskonzepte dar. Leider bieten die meisten Behandlungsmöglichkeiten nur einen geringen bis keinen Überlebensvorteil.

Abstract

The majority of patients with a squamous cell carcinoma of the head and neck region (HNSCC) initially present in a locally advanced stage of the disease. Despite aggressive protocols in first-line treatment, some of these patients develop locoregional recurrences or metastases and are, in particular, extraordinarily challenging for the multidisciplinary treatment team. Therefore, among resectability and prior therapy, age, performance status and individual expectations of the patient have to be taken into account. Apart from surgical options like salvage surgery, chemotherapy and target therapy as well as reirradiation are possible treatment concepts. Unfortunately, most treatment options offer only little to no survival benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abstract Book of the 35th ESMO Congress Milan, Italy 8–12 October 2010 (2010) Head and neck cancer. Ann Oncol 21 (Suppl 8):viii314–viii328. doi:10.1093/annonc/mdq527

    Article  Google Scholar 

  2. Austin M, Schmidt R, Parvathaneni U et al (2012) Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5515

    Google Scholar 

  3. Blumenschein GR, Glisson BS, Lu C et al (2012) Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5592

    Article  Google Scholar 

  4. Casado V, Arranz JL, Zazo S et al (2012) Role of c-MET pathway in the outcome prediction of cetuximab-based therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5520

    Google Scholar 

  5. Dalal JS, Greene JB, Hofmeister CC et al (2012) Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16027

    Google Scholar 

  6. Guigay J, Fayette J, Dillies A-F et al (2012) Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): final results of phase II trial GORTEC 2008-03. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5505

    Google Scholar 

  7. Guigay J, Fayette J, Dillies A et al (2011) Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first results of phase II trial GORTEC 2008-03. ASCO Meeting Abstracts. J Clin Oncol 29 (Suppl): abstr 5567

    Google Scholar 

  8. Langer CJ, Harris J, Horwitz EM et al (2012) Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation (XRT) in recurrent squamous cell carcinoma of the head and neck (SCCHN): long-term follow-up of Radiation Therapy Oncology Group (RTOG) protocol 9911. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5583

    Google Scholar 

  9. Langer CJ, Harris J, Horwitz EM et al (2007) Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 25:4800–4805

    Article  PubMed  CAS  Google Scholar 

  10. Seiwert TY, Keck MK, Zuo Z et al (2012) Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5517

    Google Scholar 

  11. Stoehlmacher-Williams J, Villanueva C, Foa P et al (2012) Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (−) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5504

    Google Scholar 

  12. Sukari A, Kafri Z, Heilbrun LK et al (2012) Phase II study of biweekly dose-intense docetaxel plus gemcitabine (GEM/DOC) in patients with recurrent locoregional or metastatic head and neck squamous cell carcinoma. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5534

    Google Scholar 

  13. Varadarajan P, Kotsakis AP, Martin D et al (2012) Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5541

    Google Scholar 

  14. Vermorken JB, Guigay J, Mesia R et al (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104:1691–1696

    Article  PubMed  CAS  Google Scholar 

  15. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  PubMed  CAS  Google Scholar 

  16. Vermorken JB, Peyrade F, Krauss J et al (2012) Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the ADVANTAGE phase II trial. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5516

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung(en) hin: S. Schöpper gibt an, dass kein Interessenkonflikt vorliegt. R. Knecht ist Mitglied des Advisory Boards von Merck Serono, Sanofi Aventis, Boehringer Ingelheim und Bayer Healthcare Leverkusen. S. Laban hat von Bayer Healthcare Sorafenib-Reinsubstanz für präklinische Studien erhalten.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, , Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    S. Schöpper, S. Laban, A. Münscher, R. Knecht & T. Kurzweg

  2. Medizinische Klinik und Poliklinik für Hämatologie und Onkologie, Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    B. Güldenzoph

Authors
  1. S. Schöpper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Laban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Güldenzoph
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Münscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Kurzweg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Schöpper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schöpper, S., Laban, S., Güldenzoph, B. et al. Neue Therapieaspekte bei Rezidiv und Fernmetastase des Kopf- und Hals-Karzinoms. HNO 60, 957–961 (2012). https://doi.org/10.1007/s00106-012-2596-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-012-2596-9

Schlüsselwörter

Keywords

Search

Navigation